Refining A Controversial Endpoint: Sarepta Banking On Dystrophin Levels For Golodirsen Approval In DMD
Executive Summary
While glodirsen did show higher levels of dystrophin production than eteplirsen did, increase is still unlikely to satisfy US FDA reviewers who disagreed with Janet Woodcock's decision to grant accelerated approval to eteplirsen.
You may also be interested in...
Golodirsen Rebuff: Did Exondys 51 Review Strife Influence US FDA's Decision?
Sarepta cited two safety issues when announcing a complete response letter for its exon 53 skipping DMD drug golodirsen, but the US FDA's decision may be a result of the Exondys 51 approval from 2016, analysts suggest.
OptumRx WatchList Includes Rare Disease Drugs, Potential Price Disruptors
Pharmacy benefit manager’s new pipeline report offers insight into upcoming drugs of concern to payers.
Keeping Track: US FDA Receives Submissions Galore As Year Ends
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.